| HS Code | 729582 |
| Name | Growth Hormone & Growth Hormone Releasing Factors |
| Category | Endocrinology |
| Formulation | Injectable solution |
| Active Ingredient | Somatropin or synthetic GH analogs |
| Indications | Growth hormone deficiency, pediatric growth failure, Turner syndrome, chronic renal insufficiency, adult GH deficiency |
| Route Of Administration | Subcutaneous or intramuscular injection |
| Mechanism Of Action | Stimulates growth, cell reproduction, and regeneration by targeting GH receptors |
| Contraindications | Active malignancy, acute critical illness, hypersensitivity to ingredients |
| Side Effects | Joint pain, muscle pain, edema, carpal tunnel syndrome, increased risk of diabetes |
| Regulatory Status | Prescription-only medication |
| Dosage Form | Vial, cartridge, or prefilled pen |
| Marketed By | Various pharmaceutical companies |
| Pharmacokinetics | Half-life of 2–3 hours (subcutaneous), metabolized in liver and kidneys |
As an accredited Growth Hormone & Growth Hormone Releasing Factors factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | White box with blue accents, labeled "Growth Hormone & Growth Hormone Releasing Factors," contains 10 vials (5ml each), sterile sealed. |
| Shipping | Shipping for Growth Hormone & Growth Hormone Releasing Factors is conducted under strict temperature-controlled conditions, typically requiring cold-chain logistics (2-8°C) to maintain product stability. Packaging is secure and compliant with relevant regulations for biologics. Tracking and documentation accompany each shipment, ensuring safety, quality, and timely delivery to the destination. |
| Storage | Growth Hormone and Growth Hormone Releasing Factors should be stored in a refrigerator at 2°C to 8°C. Avoid freezing, as this can damage the product. Store in the original packaging, protected from light and moisture. Once opened or reconstituted, follow the manufacturer’s instructions for duration and conditions of storage, and keep out of reach of children. |
Competitive Growth Hormone & Growth Hormone Releasing Factors prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
As a chemical manufacturer deeply involved in peptide synthesis and biologically active molecules, I’ve watched attitudes toward growth hormone therapies shift over time. Growth hormone itself—often called somatotropin—carries a weight of expectations, questions, and myths, some justified and some not. The technical expertise needed to produce it safely has grown with demand.
Production starts with a refined process that combines biotechnology and traditional chemical methods. Recombinant DNA technology enables us to create human-identical growth hormone in an environment that respects purity and batch-to-batch consistency. Over the years, the processes that seemed revolutionary in their time have become standard procedure here. Multi-stage filtration, repeated quality checks, and advanced lyophilization techniques all help ensure safety and stability. We have invested heavily in stable cell lines to yield reproducible results, minimizing the risk of impurities or byproducts. Every batch receives analytical scrutiny, especially regarding sequence integrity, correct conformation, and absence of host cell proteins or DNA.
Most customers bring questions about product types before anything else. On the market, growth hormones commonly come in two primary forms: the recombinant growth hormone itself, and the compounds known as Growth Hormone Releasing Factors (GHRFs) or Growth Hormone Releasing Hormones (GHRH). Although these terms sound similar, their differences dictate suitability for various uses.
We keep our technical sheets clear and accessible, but here are some essentials from a manufacturing standpoint. Recombinant human growth hormone generally appears as a sterile, freeze-dried white powder, intended for reconstitution in bacteriostatic water. Average vial content can range from 4 IU to 12 IU or more, depending on end-use requirements. Our specifications follow well-established international pharmacopoeial requirements for biological activity and purity—this means less than five percent aggregates, less than one percent host cell protein, and undetectable levels of bacterial endotoxins.
We have seen that growth hormone remains stable for over 24 months at -20°C or lower, given the manufacturer’s storage recommendations. After reconstitution, biological activity persists for weeks if the solution is refrigerated and protected from light. Formulation experts on our teams continually monitor excipients and stabilizing agents for compatibility with the protein. Human-grade growth hormone often ships in sealed glass vials, avoiding any exposure to soft plastics that might interact with the lyophilized drug substance.
In our experience, GHRFs differ fundamentally from the recombinant hormone. Examples include analogues such as Sermorelin, CJC-1295, Tesamorelin, and others. These synthetic peptides signal the pituitary gland to increase natural production of growth hormone rather than supplying the hormone directly. We synthesize GHRFs using advanced solid-phase peptide synthesis, followed by HPLC and MS analysis to confirm both molecular weight and sequence integrity. Consistency is always highest with the shortest and most stable sequences, but analog design can allow for longer half-life in the body.
Our team realized early on that GHRFs require superior purification steps compared to simpler peptides due to their complex structure and susceptibility to degradation. Lyophilized GHRFs remain sensitive to moisture and oxidation, so packaging always uses inert gas flushing and amber vials. As the manufacturer, we routinely see demand for variations with modified amino acids to resist enzymatic cleavage, prolonging their functional half-life in vivo.
Among medical professionals, recombinant human growth hormone treats proven endocrine deficiency—especially in pediatric patients who lack normal pituitary secretion, and in adults with confirmed growth hormone deficiency. Dosage charts and titration protocols depend on lab-confirmed baseline levels, as well as clinical goals established with a physician.
Some practitioners prefer GHRFs, believing they encourage the body’s own regulatory mechanisms. Endocrinologists tell us that in patients with functioning pituitary glands, releasing factors can provide a more “pulsatile” effect, mimicking the natural rhythm of hormone secretion. This sometimes leads to fewer side effects related to plasma IGF-1 spikes, compared to exogenous hormone administration. For fully qualified cases, either approach can be correct, but the clinical setting and careful endocrine monitoring decide the choice.
Off-label exploration of these products continues both inside and outside the clinic, including athletic and cosmetic applications. Our role as the original manufacturer is not to promote unlicensed procedures, but to supply only to authorized, licensed buyers who understand and respect regional regulations.
Chemically, the two product classes diverge sharply. Recombinant human growth hormone mirrors the 191-amino-acid sequence of native pituitary hormone. GHRFs, by contrast, usually measure less than 50 amino acids and carry targeted sequence modifications aimed at specific receptor subtypes on pituitary cells. From the perspective of large-scale synthesis, this means protein expression systems (yeast or E. coli) for growth hormone, and peptide synthesizers for GHRFs. Scale-up issues differ as well; proteins demand complex folding and stabilization during downstream purification, while peptides tolerate more straightforward chromatographic approaches.
End users also notice these distinctions beyond the molecular details. Recombinant growth hormone typically exhibits predictable dose-response effects, as it enters the bloodstream in an active form. GHRFs rely on the user’s own pituitary capacity to respond, which means results may vary—some see robust growth hormone release, others less so. This variability forms a critical difference in treatment design and monitoring.
In our experience, side effect profiles separate these products further. Direct injection of recombinant growth hormone sometimes raises risks of insulin resistance, joint discomfort, or fluid retention at higher doses. GHRFs usually carry a slightly lower risk of those complications, but side effects remain possible, such as injection site reactions or transient increases in cortisol if doses run too high.
Customers sometimes think of growth hormone as a commodity, but the science behind its manufacture denies easy shortcuts. The smallest deviation from the target sequence, the inclusion of microgram quantities of bacterial endotoxins, or trace moisture in a GHRF vial can turn a batch from therapeutic quality to outright dangerous. Early in our history, we saw how sub-par purification increased risks of immune response, antibody formation, and even severe allergic reactions. Now, analytical instruments flag irregularities before a batch ever leaves the site.
International standards continue to tighten. GMP protocols for large-molecule biologics stretch beyond simple chemical synthesis—full batch traceability, redundant quality checks, and detailed impurity quantification form an ongoing part of our workflow. Each lot receives peptide mapping and immunoassay confirmation of activity. Our team revisits production logs regularly to verify alignment with both local and international regulations for injectables. When supply is delayed, it often comes down to our insistence on full release criteria, not market pressures.
We notice growth hormone requests rising steadily, both for clinical trials and licensed therapeutic intervention. The global focus on healthy aging, in particular, brought more demand, which tests a manufacturer’s ability to supply consistent quality at scale. Sector-specific requirements appear, such as higher-purity material for pediatric endocrinology, or modified-release forms for experimental protocols.
Every increase in output risks diluting attention to the details that matter. We recently invested in continuous manufacturing equipment to minimize batch-to-batch variability and have shifted several key purification steps to closed, robotics-assisted systems. Greater automation allows us to maintain uniformity without sacrificing hands-on oversight. Our R&D group conducts regular stability studies on old and new variations, especially as regulations evolve.
We work directly with physicians and clinical scientists seeking project-specific modifications, often producing experimental analogues for early-stage investigation. If a client requests longer-acting versions of GHRF, we can conjugate the peptide to carrier proteins or introduce specific amino acid substitutions to minimize proteolytic cleavage in human plasma. Every new variant brings its own manufacturing puzzles.
Fine-tuning production scale for growth hormone and GHRFs exposes us to unexpected issues. Maintaining cell line integrity during recombinant production requires more than sterile conditions. Cells sometimes lose productivity or develop genetic drift over extended passages, shifting the purity profile of the hormone. To address this, we short-cycle cell banks and routinely sequence check primary cultures to safeguard batch consistency.
Peptide synthesis for GHRF analogues presents different technical roadblocks. Sequence complexity, peptide solubility, and tendency toward aggregation pose complications. Sequence truncation or deamidation crops up frequently as peptide chain length increases, especially if solid-phase synthesis conditions drift from target parameters. After several years’ learning curve, our teams found persistent in-process monitoring with MALDI-TOF and RP-HPLC intercepts these problems before final purification.
No production line, no matter how advanced, completely evades contamination risk. Air quality, operator training, and reagent traceability factor into every successful batch. We keep full logs of all process interventions and employ environmental monitoring in all cleanroom suites. These steps raise costs, but the alternative—unsafe or inconsistent product—remains unacceptable.
Medical products that influence endocrine systems command special attention. We recognize that improper formulation or uncontrolled release of hormone can wreak havoc. That’s why for every final fill, we use precision dispensing and container-closure integrity tests. Vial labeling includes clear lot numbers, expiry dates, and storage conditions.
Our long track record with hospital buyers, university researchers, and licensed pharmacies means every dispatch is backed by recall readiness, complaint investigation, and regulatory reporting. Local governments send inspectors to check our cleanrooms and documentation regularly, and we treat these audits as transparency opportunities rather than hurdles. We favor risk aversion—never shortcutting sterility or omitting post-release monitoring.
Feedback does not end with shipment. Many clients report back on observed stability, ease of reconstitution, and potential side effects in their populations. We feed that information back upstream into process improvements. This feedback loop anchored our decision to invest in more robust stability testing, increasingly pertinent as climate changes raise questions about cold-chain logistics worldwide.
It would be easier to market one version of growth-promoting product for every client, but direct observation over the years shows the value of treating each product class separately. Growth hormone and GHRFs occupy distinct regulatory and clinical spaces. Each responds differently to storage conditions, handling techniques, and dosing practices. For instance, a batch of recombinant growth hormone that exceeds a pH tolerance window sees aggregation and potency loss, making it unsuitable for clinical use. GHRF peptides frequently face challenges related to oxidation and peptide bond hydrolysis even at low temperatures, making their shelf life more sensitive to minor deviations in formulation.
Improper interchange between these two types based on cost or convenience can backfire. Some clinical conditions respond only to genuine growth hormone, while in others, GHRFs offer advantages tied to rhythm and physiological stimulation. For us, investing in both lines means we address differing medical and research needs responsibly. We keep each production pipeline distinct, and each batch traceable back to specific ingredient lots and manufacturing records.
Continual improvement defines our manufacturing mentality. To meet growing demand for storage-stable, ready-to-use preparations, we’ve developed pre-filled syringes and pen-cartridge systems for hormone delivery. These innovations answer feedback about dosing accuracy and patient convenience—especially valuable to young children or elderly users. For GHRFs, new carrier materials and lyophilization cycles have lengthened out-of-fridge stability and permitted simpler packaging.
We also see the need for better traceability, not just for regulators but for end users. Tamper-evident closures, QR codes for electronic verification, and serialized batch numbers give clinics and pharmacies confidence in supply authenticity. Counterfeit risk lingers in the marketplace, so these initiatives protect both users and brand reputation. Complex molecular products such as these do not tolerate grey market shortcuts—athletes, doctors, and parents all deserve certainty.
Additive manufacturing approaches have started to influence peptide synthesis too. Automated microreactors and flow synthesis platforms improve both throughput and reproducibility. By implementing digital process controls, we maintain tighter command over reaction conditions and solvent quality, slashing the risk of off-target contaminants. Scale-up bottlenecks still occur, but digital records and real-time monitoring make troubleshooting much faster than before.
We operate within an industry where trust, experience, and regulatory adherence matter more than price or volume. As manufacturers, we regularly partner with hospitals and academic units to deliver custom batches under controlled protocols for unique patient populations. Our scientists often serve as consultants in clinical trial design, helping to match product form and specifications to the needs of the study.
Science does not stand still, and neither do user profiles or health challenges. Pediatric growth hormone deficiency remains a primary concern, but demand rises from adults facing hormonal deficits secondary to injury or pituitary disorders. Research on age-related muscle loss continues to grow, frequently using both hormone and GHRF variants on protocol. Manufacturers face pressure to produce more for less, but compromise in the quality or reliability of product cannot be justified. Our responsibility as manufacturers anchors every decision, from sourcing of raw materials to final product labeling.
The next decade promises tighter oversight, novel analogues, and possibly biosimilars that challenge current product lines. Precision medicine will press for ever-purer, patient-matched formulations with trackable ingredient provenance and support for global distribution. We’re building for those challenges, expanding our analytical suite, refining IT-driven production management, and pursuing partnerships with green chemistry innovators.
Every hormone batch that leaves our facility comes with the weight of clinical reliance. We see the faces behind the prescription orders—children struggling to reach an average height, adults striving to regain strength after health setbacks, scientists testing therapies that may drive the next leap in care. Every improvement in synthesis, test protocols, or delivery packaging finds its justification in concrete benefit to real users.
Careful stewardship of growth hormone and GHRF manufacturing builds trust not just with clients but with the broader healthcare ecosystem. Staying tuned to clinic-reported outcomes, investing in compliance, and focusing on purity over quantity remain our priorities. The growth and health of patients, not just profit, defines our work and guides our choices for the future of these vital biologics.
